Alleged compliance failures at Omnicare lead to healthcare fraud lawsuit
By 
Jaclyn Jaeger2019-12-19T16:25:00
A series of alleged compliance failures at pharmaceutical services provider Omnicare has resulted in the Department of Justice intervening in yet another civil healthcare fraud lawsuit against the company.
Related articles
-
ArticleMost-trafficked content tells story of the compliance officer
Changes in the interests of our audience over the last several years help us to understand how much compliance officers must evolve in their jobs to meet the demands of a given time.
-
Blog
Omnicare to pay $28M to settle kickback allegations
Omnicare this week agreed to pay $28.1 million to resolve allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories, the Justice Department announced. Jaclyn Jaeger has more.
-
Blog
Justice Department Intervenes in Whistleblower Suits Against Omnicare
The Justice Department recently intervened in two consolidated whistleblower lawsuits against drug company Omnicare over allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories. “Although the U.S. Attorney’s Office for the Western District of Virginia is small, we will not waver in our ...
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”